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Background: Cytarabine is used in the treatment of acute myeloid leukemia (AML). Low-dose cytarabine can be
combined with valproic acid and all-trans retinoic acid (ATRA) as AML-stabilizing treatment. We have investigated
the possible risk of immunotoxicity by this combination. We examined the effects of cytarabine combined with
valproic acid and ATRA on in vitro activated human T cells, and we tested cytarabine at concentrations reached
during in vivo treatment with high doses, conventional doses and low doses.
Methods: T cells derived from blood donors were activated in vitro in cell culture medium alone or supplemented
with ATRA (1 μM), valproic acid (500 or 1000 μM) or cytarabine (0.01-44 μM). Cell characteristics were assessed by
flow cytometry. Supernatants were analyzed for cytokines by ELISA or Luminex. Effects on primary human AML cell
viability and proliferation of low-dose cytarabine (0.01-0.5 μM) were also assessed. Statistical tests include ANOVA
and Cluster analyses.
Results: Only cytarabine 44 μM had both antiproliferative and proapoptotic effects. Additionally, this concentration
increased the CD4:CD8 T cell ratio, prolonged the expression of the CD69 activation marker, inhibited CD95L and
heat shock protein (HSP) 90 release, and decreased the release of several cytokines. In contrast, the lowest
concentrations (0.35 and 0.01 μM) did not have or showed minor antiproliferative or cytotoxic effects, did not alter
activation marker expression (CD38, CD69) or the release of CD95L and HSP90, but inhibited the release of certain
T cell cytokines. Even when these lower cytarabine concentrations were combined with ATRA and/or valproic acid
there was still no or minor effects on T cell viability. However, these combinations had strong antiproliferative
effects, the expression of both CD38 and CD69 was altered and there was a stronger inhibition of the release of
FasL, HSP90 as well as several cytokines. Cytarabine (0.01-0.05 μM) showed a dose-dependent antiproliferative effect
on AML cells, and in contrast to the T cells this effect reached statistical significance even at 0.01 μM.
Conclusions: Even low levels of cytarabine, and especially when combined with ATRA and valproic acid, can
decrease T cell viability, alter activation-induced membrane-molecule expression and decrease the cytokine release.
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Intensive anticancer therapy causes an acute and severe
panleukopenia, including T lymphopenia, that may last
for 2-4 weeks [1], and after hematopoietic reconstitution
these patients usually develop a CD4+ T cell defect that
may persist for several months especially in adults [2].
This persisting T cell defect has been described both
after conventional chemotherapy as well as after autolo-
gous and allogeneic stem cell transplantation. All these
three therapeutic strategies are used in the treatment of
acute myeloid leukemia (AML), and early lymphocyte
recovery after such intensive treatment then predicts
superior relapse-free survival. This observation suggests
that early immunological events [3-6] and possibly also
cancer- or AML-related inflammation [7] are important for
AML cell survival and proliferation after chemotherapy.
Even though AML is an aggressive malignancy and
intensive chemotherapy eventually in combination with
stem cell transplantation is the most effective antileuke-
mic therapy [8], many elderly or unfit patients cannot
receive this treatment due to an unacceptable risk of
severe toxicity and early treatment-related mortality.
These patients will either receive supportive care alone
or in combination with low-toxicity AML-stabilizing
chemotherapy [8]. One such low-toxicity AML stabiliz-
ing chemotherapy is single-drug, low-dose subcutaneous
cytarabine injections usually administered as daily treat-
ment for 10 days with 4-6 weeks intervals; this treatment
can eventually be combined with oral all-trans retinoic
acid (ATRA) and valproic acid, i.e. a histone deacetylase
inhibitor [9-14]. Previous in vivo clinical studies have
shown that the triple combination of low-dose cytara-
bine, ATRA and valproic acid has immunomodulatory
effects through a normalization of the increased pre-
therapy levels of circulating Treg cells, whereas the levels
of Th17 cells are not affected by the treatment [15]. How-
ever, very little is known both about the acute and long-
term effects of such treatment on the T cell system and
whether T cell toxicity affects its antileukemic efficiency.
In the present study we therefore investigated the in vitro
effects of various cytarabine concentrations, valproic acid
and ATRA on activated T cells.
Methods
Cell donors and preparation of peripheral blood
mononuclear cells
The studies were approved by the local Ethics Committee
(Regional Ethics Committee III, University of Bergen,
Bergen, Norway) and buffy coats were derived from
healthy blood donors after informed consent. Peripheral
blood mononuclear cells (PBMC) were isolated by density
gradient separation (Ficoll-Hypaque; NyCoMed, Oslo,
Norway; specific density 1.077) from buffy coats from
seven healthy blood donors (median age 29 years; 3 maleand 4 female). Viability, proliferation and cytokine release
was examined for all individuals, CD4:CD8 ratio and
expression of activation markers were investigated only
for 3 randomly selected individuals.
Drugs
Cytarabine (Cytosine β-D-arabinofuranoside; Sigma-
Aldrich, USA) was dissolved in ddH2O to obtain a
concentration of 400 μM before aliquoted, ATRA (Sigma-
Aldrich; Oslo, Norway) was dissolved in 96% ethanol to
1 mM and valproic acid (Desitin Arzneimittel GmbH,
Hamburg, Germany) was diluted in saline to 60 mM.
All drugs were stored at -80°C. Drugs were thawed on
the same day they were used in experiments and based
on previous studies of in vivo levels the drugs were
tested at the following concentrations that are relevant
to low-toxicity AML treatment: valproic acid 1000 μM
and 500 μM [16], cytarabine 0.35 μM and 0.01 μM
[17-19], and ATRA 1 μM [20-22]. Cytarabine was also
tested at 44 μM and 1 μM corresponding to high-dose
therapy [23,24]. The relevance of these 4 cytarabine
concentrations with regard to the levels reached in vivo
is discussed in detail below in the Discussion section.
Cell culture
PBMC were suspended in pre-warmed X-Vivo 10® medium
(BioWhittaker, Cambridge, MA, USA) with 10% FBS
(Lonza Braine, Belgium) and cultured in 24-well culture
plates at a final concentration of 0.5 × 106 cells/mL (viabil-
ity and proliferation analyses) or 1 × 106 cells/mL (analysis
of activation markers). T lymphocytes were activated by 0.6
μg/mL of mouse anti-human CD3 (Pelicluster, Amsterdam,
The Netherlands) and 0.4 μg/mL of mouse anti-human
CD28 (Pelicluster). Drugs were prepared from frozen stock
solutions the same day as the experiments. Cultures were
incubated at 37°C in a humidified atmosphere of 5% CO2
before cells/supernatants were harvested.
Flow cytometric analysis of viability, proliferation and
membrane molecule expression
Flow cytometry was performed by FACS Canto II. For
each sample at least 20 000 CD5+ lymphocytes were
counted. All results were analyzed by FlowJo software
(Tree Star, Inc., OR, USA).
Proliferation and viability assay
PBMC dissolved in PBS were stained strictly according to
the manufacturer’s instructions in the CellTrace Violet
Cell Proliferation Kit (Invitrogen); thereafter cells were
washed and cultures prepared as described above. The
cells were harvested after 4 days and washed in ice-cold
PBS before being resuspended in Annexin V Bindings
buffer (BD Biosciences, Trondheim, Norway) and stained
for 15 minutes with LIVE/DEAD Far Red Fixable Dead
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gated with Alexa488 (Invitrogen, Oregon, USA) and anti-
human CD5 conjugated with PE-CY7 (clone L17F12; BD)
was added, cells were further incubated for 15 minutes
and thereafter washed in ice-cold 1% BSA/PBS before
four-color flow cytometric analysis.
Analysis of CD4/CD8 ratio and activation marker expression
Cells were harvested after 20, 44 and 68 hours of culture,
thereafter washed in ice-cold 1% BSA/PBS followed by 10
minutes of incubation in 200 μg/ml of Fc-receptor block-
ing agent (Octagam, Octapharma Ltd, Coventry, UK)
before the following anti-human antibodies were added;
FITC-conjugated anti-CD5 (L17F12; BD Biosciences),
V500-conjugated anti-CD8 (RPA-T8; BD Biosciences),
PerCPCy5.5-conjugated anti-CD4 (RPA-T4; BD Pharmingen),
PE-conjugated anti-CD25 (M-A251; BD Biosciences),
PE-CY7-conjugated anti-CD69 and APC-conjugated
anti-CD38. Cells were incubated with antibodies on ice
for 20 minutes, washed once in 1% BSA/PBS and finally
analyzed by flow cytometry.
Analysis of soluble mediator concentrations
Luminex analyses
Culture supernatants were harvested after 4 days and
stored at -80°C until analyzed. Cytokine levels were
determined by Human Cytokine Panel A Fluorokine®
Multianalyte Profiling (MAP) Kit (LUH000; R&D Sys-
tems, Abingdon, UK). All analyses were performed
strictly according to the manufacturer’s instructions.
Standard curves were constructed by using the mean of
duplicate determinations, and differences between dupli-
cates were generally <10% of the mean. The minimal de-
tectable levels were IFNγ 1.27 pg/mL, TNF-α 1.5 pg/mL,
G-CSF 1.48 pg/mL, GM-CSF 1.98 pg/mL, VEGF 1.84
pg/mL, bFGF 4.91 pg/mL, IL1RA 10.91 pg/mL, IL1α
0.36 pg/mL, IL1β 0.57 pg/mL, IL2 2.23 pg/mL, IL4 4.46 pg/
mL, IL5 0.71 pg/mL, IL6 1.11 pg/mL, IL8 1.97 pg/mL
(CXCL8), IL10 0.30 pg/mL, IL17 1.1 pg/mL, CCL2 (MCP-1)
0.47 pg/mL, CCL3 (MIP-1α) 1.45 pg/mL, CCL4 (MIP-1β)
0.74 pg/mL, CCL5 (RANTES) 1.91 pg/mL, CXCL5 (ENA-
78) 4.14 pg/mL.
Enzyme-linked immuno-sorbent analyses (ELISA)
Supernatants were harvested and stored as described
above. Mediator levels were determined by HSP90α human
EIA kit (ADI-EKS-895; Enzo Life Sciences, Exeter, UK),
HSP70 high sensitivity ELISA kit (ADI-EKS-715; Enzo Life
Science) TRAIL/TNFSF10 immunoassay (Quantikine,
R&D Systems), human CD95/Fas Ligand/TNFSF6 im-
munoassay (Quantikine, R&D Systems). All analyses were
performed strictly according to the manufacturer’s instruc-
tions. Standard curves were constructed based on the
mean of duplicate determinations, and differences betweenduplicates were generally <10% of the mean. The minimal
detectable levels were HSP90 0.05 ng/mL, HSP70 0.09
ng/mL, FasL 2.26 pg/mL, TRAIL 2.86 pg/mL.
AML patient samples and analyses
The effect of low-doses cytarabine were also tested on
primary human AML cells from 48 consecutive patients
(median age 67 years; range 24-83 years; 23 female and
25 male). Our strategy for recruitment of consecutive
patients has been described in detail previously [25]. All
patients were tested at the time of diagnosis before they
eventually received antileukemic treatment. The AML
cells were isolated from peripheral blood using density
gradient separation (Lymphoprep; Axis Shield, Oslo,
Norway) and contained at least 90% blasts. For cell via-
bility measurement, AML cells (2 × 105 cells/well) were
incubated in flat-bottomed microtiter plates (200 μl/well;
Costar 3596 culture plates; Costar, Cambridge, MA, USA)
in Stem Span SFEM™ medium (Stem Cell Technologies;
Vancouver, BC, Canada) at 37°C in a humidified 5% CO2
incubator for 40 hours before the percentage of viable
cells was determined by flow cytometry after staining with
propidium iodide (PI) and Annexin V. Furthermore, for
the proliferation assay 5 × 104 AML cells/well were cul-
tured in flat-bottomed microtiter plates (200 μl/well) in
Stem Span for six days prior to addition of 37 kBq of
3H-thymidine (Perkin Elmer) to each well and incubated
for 18 hours before cells were harvested and radioactive
activity determined. The medium used in the proliferation
assay was supplemented with the growth factors (20 ng/ml)
G-CSF, SCF and Flt3l.
Statistical analyses
Statistical comparisons were made by using GraphPad
PRISM (version 5.0, GraphPad Software, Inc., USA) with
repeated measures ANOVA (within-subjects ANOVA or
ANOVA for correlated samples) with Dunnett’s Multiple
Comparison Test (post-test). Differences were regarded as
significant when p <0.05. Cluster analyses were performed
by the use of J-Express 2011 analysis suite (MolMine AS,
Bergen, Norway). The AML cell data were analysed with
the IBM Statistical Package for the Social Sciences (SPSS)
version 21 using pair sampled t-test and the Wilcoxon
signed rank test to compare drug-containing and drugfree
cultures.
Results
ATRA and low doses of valproic acid do not affect
viability and proliferative capacity of activated normal
T cells, whereas cytarabine has a dose-dependent
antiproliferative and proapoptotic effect
PBMC derived from healthy blood donors (n = 7) were
activated in vitro with anti-CD3 plus anti-CD28 during
4 days of culture in medium alone or medium
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1000 μM or cytarabine 0.01-44 μM. The viability
(Figure 1; Annexin-PI assay) and proliferation (Figure 2;
the CellTrace Violet Cell proliferation assay) of CD5+ T
cells were then analyzed by flow cytometry. ATRA and
valproic acid (500 μM) did not cause any statistically
significant alteration of T cell viability or proliferation.
A small, but statistically significant, decrease in proliFigure 1 Viability of activated T lymphocytes after exposure to cytarabine,
healthy blood donors (n = 7) were cultured in vitro with T cell activating an
after 4 days of culture in medium alone or with the indicated drugs. (A) Th
shown for a control sample and the corresponding sample of cells expose
staining with the LIVE/DEAD Far Red Fixable Dead Cell Stain, (ii) apoptotic
Annexin V positive, and (iii) dead when being LIVE/DEAD Far Red Fixable D
stacked bar graphs for the control samples and samples exposed to the in
mean percentages for viable, dead and apoptotic CD5+ T cells. A repeated
to determine statistically significant differences (*p <0.05; **p <0.01; ***p <feration was detected after exposure to valproic acid
(1000 μM). In contrast, cytarabine caused a dose-
dependent reduction both in viability and proliferation.
An increased fraction of apoptotic cells was then
detected together with the decreased viability in the
cytarabine-containing cultures; an observation suggesting
that the decreased viability is caused by drug-induced
apoptosis.ATRA and valproic acid alone or in combinations. PBMCs derived from
ti-CD3 and anti-CD28, and the viability was analyzed by flow cytometry
e gating strategy to analyze the viability of CD5+ T lymphocytes is
d to cytarabine 44 μM. T cells were defined as (i) viable when negative
when being LIVE/DEAD Far Red Fixable Dead Cell Stain negative and
ead Cell Stain positive. (B) The overall results are summarized as
dicated drugs or drug combinations. The results are presented as the
measure ANOVA with Dunnett’s Multiple Comparison Test was used
0.001).
Figure 2 Proliferation of activated T lymphocytes after exposure to cytarabine, ATRA and valproic acid alone or in combinations. PBMCs derived
from healthy blood donors (n = 7) were stained with the cell proliferation dye CellTrace™ Violet and subsequently activated by in vitro culture in
the presence of anti-CD3 and anti-CD28. Flow cytometric analysis of proliferation was done after 4 days of culture in medium without drugs
(control) or in the presence of drugs/drug combinations. (A) The gating strategy to measure the proliferative response of CD5+ T lymphocytes is
shown for three representative samples (two control samples –unstimulated and stimulated– and one sample with cytarabine 44 μM). Cultures
without anti-CD3 and anti-CD28 and thereby no proliferating cells were used as the negative gating control. (B) The overall results are presented
as bar graphs for the control samples and samples exposed to the indicated single drugs or drug combinations. Results are presented as the
mean percentages (with SD) of proliferative T cells. A repeated measure ANOVA with Dunnett’s Multiple Comparison Test was used to determine
statistically significant differences (*p <0.05; **p <0.01; ***p <0.001).
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cytarabine on normal human T cells
As described above, normal PBMC were activated in the
presence of various drug combinations (Figures 1 and
2). Proliferation and viability was not altered for cultures
containing various combinations of ATRA and valproic
acid, and ATRA alone did not alter the antiproliferative
or proapoptotic effects of cytarabine.
Valproic acid 500 and 1000 μM was also combined
with cytarabine 0.01 and 0.35 μM; these cytarabineconcentrations correspond to the in vivo levels reached
during low-dose cytarabine treatment when the drug can
be combined with ATRA and valproic acid [15,26,27].
Cytarabine 0.01 μM alone did not have any antiprolifera-
tive effect but a statistically significant antiproliferative ef-
fect was observed when cytarabine at this concentration
was combined with valproic acid 1000 μM (Figure 2).
Similarly, when cytarabine at a higher concentration of
0.35 μM was present together with valproic acid an in-
creased antiproliferative effect was observed with valproic
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drug combinations did not have significant effects on T
cell viability, the only exception being cytarabine 0.35 μM
in combination with valproic acid 500 μM (Figure 1).Figure 3 The CD4:CD8 ratio of activated T lymphocytes after exposure to c
derived from three healthy blood donors were activated by anti-CD3 plus
analysis of the CD4:CD8 ratio. Cultures were prepared without drugs, with
gating strategy for estimation of CD4+CD5+ and CD8+CD5+ T cells lymphocy
as bar graph (mean ratio with SD) for the drugfree control cultures and cultur
A repeated measure ANOVA with Dunnett’s Multiple Comparison Test was us
***p <0.001).The CD4:CD8 ratio is altered only by high-dose cytarabine
but not by ATRA, valproic acid or low-dose cytarabine
Normal PBMCs derived from 3 healthy individuals were
activated as described above in the presence of variousytarabine, ATRA and valproic acid alone or in combination. PBMCs
anti-CD28 during 3 days of in vitro culture before flow cytometric
single drugs or with drug combinations. (A) The figure shows the
tes in a representative experiment. (B) The overall results are presented
es prepared with the indicated single drugs or drug combinations.
ed to determine statistically significant differences (*p <0.05; **p <0.01;
Figure 4 (See legend on next page.)
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Figure 4 Expression of the CD69 and CD38 activation markers by anti-CD3 plus anti-CD28 activated CD8+ T lymphocytes – effects of cytarabine,
ATRA and valproic acid tested alone or in combination. PBMCs derived from three healthy donors were activated during in vitro culture with
anti-CD3 and anti-CD28, and flow-cytometric analysis of surface CD69 and CD38 expression was performed after 20, 44, and 68 hours of culture.
(A) The figure shows the mean fluorescence intensity (MFI) of surface CD69 and CD38 expression by CD8+CD5+ T lymphocytes in drugfree
control cultures after 20, 44, and 68 hours (median and range, three experiments). (B) The overall results for CD69 expression are presented as bar
graph (median MFI and range) for CD8+CD5+ T lymphocytes cultured in vitro for 20, 44, and 68 hours in the presence of the indicated single
drugs or drug combinations. (C) The overall results for CD38 expression are presented as bar graph (median MFI and range) for CD8+CD5+ T
lymphocytes cultured in vitro for 20, 44, and 68 hours in the presence of the indicated single drugs or drug combinations. Repeated measures
ANOVA with Dunnett’s Multiple Comparison Test was for the statistical analyses (*p <0.05; **p <0.01; ***p <0.001).
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μM) caused a dose-dependent reduction both in viability
and proliferation. Proliferation, but not viability, was al-
tered for cultures containing several of the dual or triple
drug combinations. However, the CD4:CD8 ratio was
significantly increased only by the highest cytarabine
concentration of 44 μM whereas the ratio was not
altered when the cells were cultured with single drugs at
the other concentrations or any dual or triple drug com-
bination (Figure 3).
ATRA and valproic acid alters the expression of the CD69
and CD38 activation markers by CD4+ and CD8+ normal T
cells whereas cytarabine has only minor effects
In our experimental model CD69 showed an expected
high early expression after 20 hours of culture with anti-
CD3 plus anti-CD28 both for CD4+ and CD8+ T cells,
and thereafter it decreased gradually when tested after
44 and 68 hours. In contrast, CD38 showed a gradual
increase for both T cell subsets during the same period
after activation (3 healthy individuals tested).
Even though ATRA 1 μM and valproic acid 500 and
1000 μM had no or only minor effects on T cell prolifer-
ation and viability as well as the CD4:CD8 ratio, both
drugs prolonged the expression of CD69 both for CD4+
and CD8+ T cells, and significantly increased expression
was detected after 44 hours (3 healthy individuals tested,
Figures 4 and 5). Cytarabine had a similar increasing
effect on CD69 expression for both T cell subsets but
only when testing the highest concentration (44 μM).
The drugs showed additive enhancing effects on CD69
expression both for CD4+ and CD8+ T cells when testing
double or triple combinations, and highly significant dif-
ferences could then be detected (i) for CD4+ T cells
when combining ATRA and valproic acid 500 μM; and
(ii) especially for CD4+ cells but also CD8+ T cells when
ATRA/valproic acid were combined with low cytarabine
concentrations (0.01 and 0.35 μM, p <0.001).
ATRA and valproic acid had opposite effects on CD38
expression by activated T cells; ATRA increased the
expression whereas valproic acid decreased the early ex-
pression of this marker both for CD4+ and CD8+ T cells.
None of these effects were detected after 68 hours. In
contrast, cytarabine did not alter CD38 expression forany concentration tested (0.01, 0.35, 1 and 44 μM). The
ATRA-induced enhancement was only maintained in
the presence of cytarabine (both for CD4+ and CD8+ T
cells) but not in the presence of ATRA alone. Finally,
the valproic acid-induced reduction of CD38 levels was
maintained in the presence of cytarabine and the triple
combinations did not alter CD38 expression.
Cytarabine 44 μM decreased CD25 expression of CD4+
T cells but only after 68 hours of culture (p <0.05). No
other single drug or drug combinations altered CD25
expression by activated CD8+ and CD4+ T cells at any
time point tested (data not shown).
The combination of cytarabine, valproic acid and ATRA
reduces the release of FasL and HSP90 but have only
weak effects on the release of TRAIL and HSP70 by
activated T cells
Normal PBMC derived from 7 healthy individuals were
activated with anti-CD3 and anti-CD28 and cultured for
4 days in vitro with or without valproic acid, ATRA or/
and cytarabine alone or in combination before super-
natant levels of FasL, TRAIL HSP70 and HSP90 were
determined (Figure 6). Both valproic acid and cytarabine
caused a dose-dependent reduction of HSP90 and FasL.
However, the reduction in single-drug cultures was rela-
tively small and the most significant decreases were seen
for drug combinations and strong reductions were then
seen even when combining drugs at concentrations
(cytarabine 0.01 and 0.35 μM, valproic acid 500 μM) that
did not cause significant reductions when tested alone.
In contrast, the drugs had either no significant or only
weak effects on the release of TRAIL and HSP70.
Only high cytarabine concentrations show a broad
inhibitory effect on the cytokine release profile by
activated T cell whereas high-level valproic acid as well
as combinations of low valproic acid-cytarabine levels
inhibits the release of a minor cytokine subset
PBMC derived from 7 healthy individuals were cultured
with anti-CD3 plus anti-CD28 for 4 days before super-
natant cytokine levels were determined for cultures pre-
pared in medium alone and medium with ATRA 1 μM,
valproic acid 500 and 100 μM, and cytarabine 0.01, 0.35,
1 and 44 μM. Each drug was tested alone and in the dual
Figure 5 (See legend on next page.)
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Figure 5 Expression of the CD69 and CD38 activation markers by anti-CD3 plus anti-CD28 activated CD4+ T lymphocytes – effects of cytarabine,
ATRA and valproic acid tested alone or in combination. PBMCs derived from three healthy donors were activated during in vitro culture with
anti-CD3 and anti-CD28, and flow-cytometric analysis of surface CD69 and CD38 expression was performed after 20, 44, and 68 hours of culture.
(A) The figure shows the mean fluorescence intensity (MFI) of surface CD69 and CD38 expression by CD4+CD5+ T lymphocytes in drug-free
control cultures after 20, 44, and 68 hours (median and range, three experiments). (B) The overall results for CD69 expression are presented as bar
graph (median MFI and range) for CD4+CD5+ T lymphocytes cultured in vitro for 20, 44, and 68 hours in the presence of the indicated single
drugs or drug combinations. (C) The overall results for CD38 expression are presented as bar graph (median MFI and range) for CD4+CD5+ T
lymphocytes cultured in vitro for 20, 44, and 68 hours in the presence of the indicated single drugs or drug combinations. Repeated measures
ANOVA with Dunnett’s Multiple Comparison Test was for the statistical analyses (*p <0.05; **p <0.01; ***p <0.001).
Figure 6 The release of FasL, TRAIL, HSP70 and HSP90 by anti-CD3 plus anti-CD28 activated normal T cells – effects of cytarabine, ATRA and
valproic acid tested alone or in combination. The supernatant concentrations of FasL, TRAIL, HSP90 and HSP70 were determined after 4 days of
PBMC culture with anti-CD3 plus anti-CD28. Cultures were prepared in medium alone or together with the single drugs or drug combinations
indicated in the figures. (A) The upper figure presents the FasL (left panel) and TRAIL (right panel) levels, the lower figure (B) presents the levels
of HSP90 (left panel) and HSP70 (right panel). All results are presented as the mean with SD. Repeated measures ANOVA with Dunnett’s Multiple
Comparison Test against control samples were used for statistical analyses (*p <0.05; **p <0.01; ***p <0.001).
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overall cytokine results are presented in Additional file 1:
Tables S1-S4, and the results are summarized in a two-
ways hierarchical cluster analysis including 20 cytokines
and in addition FasL, TRAIL, HSP70 and HSP90 (Figure 7).
We investigated the levels of (i) the immunoregulatory cy-
tokines IFNγ and TNFα; (ii) the growth factors G-CSF,
GM,-CSF, VEGF and bFGF; (iii) the chemokines CCL2-5
and CXCL5; and (iv) the interleukins IL1α, IL1β, IL1RA,
IL2, IL4-6, IL8, IL10 and IL17. For this two-way hierarch-
ical cluster analysis the cytokine levels in drug-containingFigure 7 The soluble release profile by activated T cells is altered by valpro
PBMCs derived from 7 healthy individuals were cultured with the T cell act
were harvested and cytokine levels determined. The cells were then cultur
acid 500 and 100 μM, and cytarabine 0.01, 0.35, 1 and 44 μM, and each dru
top of the figure. The overall results are presented in detail in Additional file 1
including FasL, TRAIL, HSP70 and HSP90 together with 20 cytokines are prese
cytokines IFNγ and TNFα; (ii) the growth factors G-CSF, GM,-CSF, VEGF and bF
IL1β, IL1RA, IL2, IL4-6, IL8, IL10 and IL17. The cytokines formed 4 main clusters
19 single drug/drug combinations used throughout the study and the varioucultures were made relative to the level in the correspond-
ing drugfree control, and the mean relative level of each
drug-cytokine combination was used for the analysis that
included the 24 soluble mediators and the 19 single drug/
drug combinations. The drugs/drug combinations formed
three main clusters:
 Only cytarabine 44 μM reduced the levels of a
majority of the soluble mediators (Figure 7 right
margin, lower and upper middle mediator clusters),
including HSP90 as well as several chemokinesic acid, ATRA and cytarabine – a two-ways hierarchical cluster analysis.
ivating signal anti-CD3 plus anti-CD28 for 4 days before supernatants
ed in drugfree control cultures and together with ATRA 1 μM, valproic
g was also tested in dual or triple combinations as indicated at the
: Table S1-S4. The results from a two-ways hierarchical cluster analysis
nted in the figure. We investigated the levels of (i) the immunoregulatory
GF; (iii) the chemokines CCL2-5 and CXCL5; and (iv) the interleukins IL1α,
as indicated on the left margin of the figure. The analysis included the
s drugs/drug combinations formed three main clusters.
Figure 8 Effects of low-dose cytarabine on the viability and proliferation
of primary human AML cells. (A) The viability of primary human AML
cells after 40 hours of in vitro culture in medium alone. Cytarabine seems
to have a dose-dependent toxic effect, but the difference reached
statistical significance only for the two highest drug concentrations
(0.5 and 0.05 μM). (B) Low-dose cytarabine showed a dose-
dependent antiproliferative effect for the leukemic cells when
testing cytokine-dependent AML cell proliferation (medium
supplemented with 20 ng/mL of GM-CSF, SCF and Flt3l). The
growth inhibition reached statistical significance even when testing
cytarabine 0.01 μM. All results are presented as the mean with SD, the
pair sample t-test was used for the statistical analyses of the apoptosis
data, and the Wilcoxon signed rank test for the proliferation data
(*p <0.05; **p <0.01; ***p <0.001).
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(IL4-6, IL10, IL17).
 A second cluster was mainly formed by (i) all triple
combinations, (ii) the two valproic acid + ATRA
combinations and (iii) valproic acid 1000 μM tested
alone or in combination with low-level cytarabine.
This cluster was characterized by decreased release
of the lower mediator cluster similar to cytarabine
44 μM and in addition a relatively weak effect for
the lower middle cluster.
 For the other drugs/combinations we only observed
weak and divergent effects.
Thus, only high cytarabine levels show a broad and
strong inhibition of the T cell cytokine response, whereas
high valproic acid levels 1000 μM as well as all triple
combinations of low-level cytarabine, low-level valproic
acid and ATRA inhibit the release of a defined subset of
T cell derived mediators.
Low cytarabine concentrations show little effect on
patient cell viability but significantly reduce their
proliferation capability
We investigated the effect of low-dose cytarabine on cell
viability and proliferation for AML cells derived from 48
consecutive patients. As described previously the AML
cell viability varies widely between patients after in vitro
incubation due to spontaneous in vitro apoptosis [28],
and the median viability in our drug-free control cultures
was 34% (range 2-64%) in the control samples. We investi-
gated cytarabine 0.5, 0.05 and 0.01 μM (Figure 8A), and
the viability was significantly reduced only for the two
highest drug concentrations (0.5 μM, median viability
26%, p <0.001; 0.05 μM, median viability 32%, p =0.030).
In contrast, all three cytarabine concentrations reduced
AML cell proliferation significantly. The median radio-
activity corresponded to 5900 counts per minute (cpm)
for the drugfree controls (range <1000 – 179200), the
activity was only 600 cpm for cytarabine 0.5 μM (p <0.001),
900 cpm for cytarabine 0.05 μM (p <0.001) and 1800 cpm
for cytarabine 0.01 μM (p <0.001) (Figure 8B).
Discussion
Low-toxicity AML-stabilizing treatment is now tried for
patients who are unfit for intensive and potentially cura-
tive therapy. The HDAC inhibitor valproic acid has been
investigated as an antileukemic agent in several clinical
studies, usually in combination with ATRA [15] and/or
low-dose cytotoxic agents [29]. Three phase II clinical
studies have shown that the combination of valproic
acid, ATRA and low-dose cytarabine [15,26,27] has low
clinical toxicity and can induce complete remission for a
minority and disease stabilization for a larger subset of
elderly and unfit patients. Despite low clinical toxicity,our in vitro results suggest that the treatment may have
immunosuppressive effects as we observed decreased T cell
viability, reduced T cell proliferation, altered activation-
induced expression of membrane molecules and reduced
cytokine release (see Table 1 for summary).
Cytarabine is commonly used in AML therapy and is
then used at single doses ranging from 10 mg/m2 up to
3000 mg/m2 [30]. The systemic serum levels therefore
show a wide variation depending both on the single
dose, the administration form and the gender with faster
clearance in males [30]. Firstly, the daily doses com-
monly used in induction treatment of human AML are
100-200 mg/m2; the drug can then be given as intermit-
tent injections or as continuous infusions and the clear-
ance is also influenced by the pretreatment leukemia
blast count in the blood. The average steady state levels
Table 1 A summary of pharmacological effects on T cell activation; studies of high cytarabine concentrations alone,
low cytarabine levels and low cytarabine levels in combination with ATRA and/or valproic acid
Parameter High cytarabine levels
(44 and 1.0 μM)
Low cytarabine
levels (0.35 and 0.01 μM)
Low cytarabine levels (0.35 and 0.01 μM)
combined with ATRA 1 μM and/or valproic
acid (500 and 1000 μM)
T cell viability Decreased, apoptosis
induction
Decreased only for 0.35 μM No significant effect for most combinations
T cell proliferation Decreased Decreased only for 0.35 μM A highly significant decrease for combinations
with cytarabine 0.35 μM
CD4:CD8 ratio Decreased No effect No effect
CD69 expression Prolonged expression,
especially for CD8+ but
also CD4+ cells
No effect both for CD4+
and CD8+ cells
CD4+ cells: Increased by ATRA and decreased
by valproic acid, no effect when combining
these two drugs. The ATRA effect maintaining
when combined with cytarabine. CD8+ cells:
Increased by ATRA and valproic acid, the
increase was also seen in combinations with
cytarabine.
CD38 expression No effect No effect both for CD4+
and CD8+ cells
CD4+ cells: Increased by ATRA and decreased
by valproic acid, the ATRA effect maintained
in the presence of cytarabine. CD8+ cells:
Increased by ATRA and decreased by valproic
acid, the ATRA effect maintained in
combinations.
FasL release Decreased No effect Strong decrease in all combinations also with
cytarabine 0.01 μM
TRAIL release Minor decrease only at 44 μM No effect Minor effects
HSP90 release Decreased No effect Strong decrease both for cytarabine 0.35 and
0.01 μM
HSP70 Increased No effect No effect for all except one combination
Cytokine release;
hierarchical cluster
analysis including 24
soluble mediators
Decreased levels for two out of 4 main
clusters including 9 cytokines, including the
cluster showing decreased levels for the drug
combinations.
Only minor effects Decreased levels only for one out of the four
main clusters, including 4 cytokines
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0.8 μM for 100 and 200 mg/m2/day, respectively [31].
Levels will be higher when giving these daily doses as in-
jections. Secondly, the drug may also be used at single
doses up to 3 g/m2 twice daily administered as short-
time infusions and resulting in peak concentrations
during a 3-hours infusion averaging 50-100 μM [30,31].
Finally, cytarabine is used as low-toxicity subcutaneous
injections (10-20 mg/m2) once or twice daily usually for
a 10 days period with 4-6 weeks intervals [15]; the steady
state levels are then below 0.1 μM [30,32-35] and the peak
levels after a subcutaneous injection of 10 mg/m2/12
hours can be up to 0.2-0.5 μM [18]. In our present study
we therefore investigated the concentrations (i) 44 μM
that corresponds to peak levels during high-dose treatment;
(ii) 1 μM that is reached when using the conventional
doses of 100-200 mg/m2; and (iii) and 0.35 and 0.01 μM
that correspond to levels reached early after and during
steady state of low-dose treatment.
Cytarabine effects on T cell activation were concen
tration-dependent; decreased viability was only seen for the
higher concentrations and this is in accordance with previ-
ous studies suggesting that cytarabine has cytotoxic effectsonly at concentrations above 100 nM [30]. However, cytar-
abine had immunoregulatory effects even at lower level.
Several of our present observations suggest that the cytara-
bine effects on activated T cells at least partly differ
between T cell subsets. This is supported both by (i) the al-
tered CD4:CD8 ratio after exposure to high cytarabine
levels, (ii) the differences between CD4+ and CD8+ T cells
with regard to cytarabine effects on CD38 and CD69 ex-
pression during T cell activation; and (iii) previous studies
describing that in vivo treatment with our triple combin-
ation causes normalization of the increased pre-therapy
levels of circulating Treg cells, whereas the levels of circu-
lating Th17 cells are not affected by the treatment [15].
Cytarabine decreased AML cell viability only when tested
at 0.5 and 0.05 μM but not at the lowest concentration,
whereas the drug inhibited AML cell proliferation even at
0.01 μM. In contrast, T cell proliferation was inhibited only
at cytarabine concentrations ≥0.35 μM. Thus, based on the
proliferation studies we conclude that primary AML cells
are more susceptible to cytarabine than normal T cells;
suggesting that there is a therapeutic window for cytara-
bine treatment that makes it possible to achieve antileuke-
mic effects in vivo before severe T cell toxicity occurs.
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affected T cell activation but only for a minority of our
experimental models and usually when testing the high-
est concentration of 1000 μM that corresponds to a level
slightly above the recommended therapeutic serum level
[15]. ATRA did not affect T cell activation in most of
our studies. However, both drugs contributed to the
effects of the triple combination of T cell activation, and
in several of our models highly significant immuno-
modulatory effects were seen only when testing the
triple combination.
Early lymphoid reconstitution after intensive and po-
tentially curative antileukemic therapy is associated
with decreased risk of later AML relapse, suggesting
that post-treatment immunological events are clinically
important to maintain disease control and complete
hematological remission after end of treatment [36,37].
This association between early lymphoid reconstitution
and survival has also been observed after conventional
intensive chemotherapy [3], autotransplantation [4] and
allotransplantation [5,6]. The mechanisms behind this
association are not known [38], but taken together
these observations suggest that not only allogeneic but
also autologous antileukemic T cell reactivity after in-
tensive treatment or autotransplantation is clinically
important.
To the best of our knowledge no previous studies
have investigated whether such autologous antileuke-
mic T cell reactivity is important also in patients receiv-
ing AML-stabilizing treatment, e.g. the combination of
ATRA, valproic acid and cytarabine. There are two
major differences between AML patients receiving
intensive treatment and patients receiving our low-toxicity
triple combination: (i) most patients receiving stabilizing
treatment do not achieve complete hematological re-
mission, and (ii) these patients will often receive con-
tinued therapy until disease progression. Furthermore,
many AML patients have severe leucopenia, including
T lymphopenia [16]. During the continued AML-
stabilizing treatment most of these patients thus have a
combined AML-induced quantitative and treatment-
induced qualitative T cell effect. Most of the patients
who respond to the treatment do not show increased
leukocyte counts [16,39]. If antileukemic immune reactiv-
ity is important for the efficiency of AML-stabilizing treat-
ment similar to its effect in patients receiving intensive
therapy, the immunosuppressive effects described in our
present study may influence the efficiency of this treat-
ment. The question should be addressed in future clin-
ical studies, and one should then especially investigate
whether the effect differs between various T cell
subsets.
Three clinical studies have previously investigated the
antileukemic effect of low-dose cytarabine, ATRA andvalproic acid [13,39,40], but the question of immunosup-
pression was only addressed in one of them [39]. This
study showed that even though the drug-induced im-
munosuppression may be important for the antileukemic
efficiency of AML-stabilizing (see above), the triple com-
bination does not seem to have a major impact on the risk
of complicating infections in responders to the treatment
as these patients usually stayed outside hospital without
severe infections as long as the disease was stable without
signs of AML progression [39]. However, it should be em-
phasized that these patients were treated with even a
lower cytarabine dose than commonly used for low-dose
cytarabine treatment [39], and in contrast to the other two
studies ATRA was administered as an intermittent ther-
apy with 2 weeks of treatment at 12 weeks intervals. Our
studies suggest that clinically relevant immunosuppression
may occur if standard low-dose cytarabine or continuous
ATRA therapy is used.
The valproic acid-ATRA-cytarabine combination altered
T cell release of several soluble mediators. Firstly, FasL
(CD95L) and TNF-related apoptosis-inducing ligand
(TRAIL or APO2) may mediate autocrine activation-
induced cell death (AICD) to maintain self-tolerance
and suppress immune responses [41,42], but soluble
CD95L may also induce non-apoptotic signals that pro-
mote cell migration [43]. The effects of single drugs
and especially our triple combination on FasL release
suggest that the treatment may alter cell trafficking.
Secondly, the intracellular chaperones HSP90 and
HSP70 can be released extracellularly and will then
have immunomodulatory effects [44-47]; these effects
may be affected by the altered HSP90 levels during T
cell activation in the presence of our triple combination.
Finally, both cytarabine, valproic acid and ATRA affected
the release of several interleukins and chemokines by
activated T cells. Taken together these observations
suggest that the antileukemic triple combination not
only has direct effects on T cells, but probably also in-
direct effects on other immunocompetent cells medi-
ated by the altered release of soluble mediators during
T cell activation.Conclusions
Both previous in vivo studies and the present in vitro
studies suggest that the triple combination of low-dose
cytarabine, ATRA and valproic acid has immunomodu-
latory effects, and as discussed above these effects may
differ between various T cell subsets. The triple com-
bination has direct effects on the T cells, but it may also
affect other immunocompetent cells through the
altered release of soluble mediators during T cell activa-
tion. This possible risk of immunosuppression should
be further investigated in future clinical studies.
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